Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Free cash flow margin

Free cash flow margin at other companies

Pfizer logo
PfizerPFE
18%+8.8pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
24.2%-2.9pp
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
21.7%-1.0pp
PTC Therapeutics logo
PTC TherapeuticsPTCT
39.1%+32.8pp
Insmed logo
InsmedINSM
-71%-28.6pp
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
-563.9%-954pp

Other financials

Income statement

See full
Revenue$401.3M-34.3%
Operating income$13.3M-88.5%
Net income-$4.9M-102%
EPS (diluted)-$0.05-103%

Balance sheet

See full
Cash & equivalents$571.1M+11.9%
Total debt$198.2M-7.6%
Total equity$1.5B+8.8%
Total assets$3.2B-13.4%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$555.0K-98.3%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.77B+10.9%
Enterprise value$1.4B+7.5%
P/S0.9×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin-6.9%

Returns & leverage

See full
Return on equity-9.3%+2,662pp
Debt / equity0.1×0.0×
Current ratio4.4×+1.5×

Where this comes from

Calculated from Sarepta Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed November 6, 2025. Open the filing →

Filed
Nov 6, 2025
Fiscal quarter
Q3 FY2025
Calendar quarter
Q3 2025
Accession
0001193125-25-269436

FAQ

What is Sarepta Therapeutics, Inc.'s free cash flow margin?
Sarepta Therapeutics, Inc. (SRPT) reported free cash flow margin of -28.7% in Q3 2024.
How has Sarepta Therapeutics, Inc.'s free cash flow margin changed year-over-year?
Sarepta Therapeutics, Inc.'s free cash flow margin increased by 47.5% year-over-year, from -54.6% to -28.7%.
What is the long-term trend for Sarepta Therapeutics, Inc.'s free cash flow margin?
Over 2 years (2021 to 2023), Sarepta Therapeutics, Inc.'s free cash flow margin has grown at a -17.8% compound annual growth rate (CAGR), from -68.6% to -46.4%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.

Ask your AI about Sarepta Therapeutics, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude